Is Teva Pharmaceutical Industries (TEVA) Still Undervalued Following Its Recent Pullback?

Teva Pharmaceutical Industries Stock Moves Set Against Recent Performance

Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after a mixed short term performance, with the share price down about 2% over one day and 5% over the past week.

Across longer windows, the stock has posted a small gain over the past month and a much stronger advance over the past 3 months. This has left investors weighing how these swings relate to Teva’s underlying pharmaceutical portfolio and reported financials.

Set against this choppy spell, Teva Pharmaceutical Industries has still produced strong momentum, with a 90 day share price return of 38.77% and a 1 year total shareholder return of 113.03%. This points to investors reassessing both its growth prospects and risk profile at a US$39.41 share price.

Compare Teva Pharmaceutical Industries' sharp 1 year rebound with a curated 28 high quality undervalued stocks that also pair solid fundamentals with recent share price momentum.

After a 1 year total return above 100% and a recent pullback, Teva Pharmaceutical Industries now sits at US$39.41. Does that set up a fresh entry, or does it argue for patience until the valuation cools further?

Most Popular Narrative: 17% Undervalued

On Simply Wall St's most followed narrative, Teva Pharmaceutical Industries carries a fair value estimate of $47.58 against the latest $39.41 close. This frames the recent pullback as a move inside a still optimistic long term story.

The shift in Teva Pharmaceutical Industries toward higher value branded CNS drugs such as AUSTEDO, AJOVY and UZEDY is increasing the share of revenue tied to products that currently carry higher gross margins. Management links this shift to the goal of non GAAP operating margins of 30% and a higher EBITDA contribution over time.

See why 6 investors see Teva Pharmaceutical Industries as 17% undervalued.

This widely tracked narrative applies an 8.64% discount rate and arrives at a fair value that sits about 17% above the current share price, with analysts also clustering around a $47.58 target anchored to higher margin CNS therapies, biosimilars and continued balance sheet repair. At $39.41, the market price reflects a very different stance on Teva Pharmaceutical Industries than the scenario where earnings reach $2.8b and margins improve toward the mid teens over the coming years.

Result: Fair Value of $47.58 (UNDERVALUED)

Still, the Teva Pharmaceutical Industries story can be knocked off course if key pipeline launches underperform, or if the concentrated branded portfolio faces competitive or pricing pressure.

Find out about the key risks to this Teva Pharmaceutical Industries narrative.

Next Steps

If the mixed signals around Teva Pharmaceutical Industries leave you unsure, that uncertainty is exactly why you should look at the underlying data yourself and move quickly. To weigh both the concerns and the potential upside, start with the full picture of 4 key rewards and 3 important warning signs.

Looking For More Investment Ideas Beyond Teva Pharmaceutical Industries?

Do not stop your research with Teva Pharmaceutical Industries when a wider universe of opportunities is only a few clicks away on the Simply Wall St screener.

• Target stability in your portfolio by scanning a 30 resilient stocks with low risk scores that focuses on businesses with more resilient risk profiles and fewer financial red flags.
• Hunt for quality at a reasonable price by reviewing a 28 high quality undervalued stocks that highlights companies combining solid financials with compressed valuations.
• Spot potential future leaders early by checking a 21 high quality undiscovered gems that filters for strong fundamentals where attention has not yet fully arrived.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com